Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist

Global Pharmacogenomics (PGx) Market Analysis: Focus On Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography– Estimation & Forecast 2022

Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.

SKU: BH007A
Published Year: 2016
 
 

Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are further enhancing the platform for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created the platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market but the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years. 

Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics,  and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations. 

Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease. The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing the same. 

TABLE OF CONTENT
1 Report Overview
1.1 Report Scope
1.1.1 Report Coverage
1.1.2 Assumptions And Limitations
1.1.3 Market Classification & Segmentation
1.2 Research Methodology
1.2.1 Data Points Considered For Market Size Estimation
1.2.2 Key Data Point Sources
1.2.2.1 Key Data Points From Primary Sources
1.2.2.2 Key Data Points From Secondary Sources
1.2.3 Data Triangulation
1.2.4 Top-Down Approach
1.2.5 Bottom-Up Approach
1.3 Report Description
2 Executive Summary
2.1 Global Market Scenario
3 Market Overview
3.1 Introduction
3.2 Pharmacogenomics: Mechanism Of Action
3.3 Role Of Companion Diagnostics In PGX
3.4 Role Of Biomarkers In PGX
3.5 Role Of Molecular Diagnostics In PGX
3.6 Benefits Of PGX
3.7 End-Use Applications Of PGX
3.8 Market Dynamics
3.8.1 Market Drivers
3.8.2 Market Challenges
3.8.3 Market Opportunities
4 Competitive Insights
4.1 Key Market Developments & Strategies
4.1.1 Competitive Landscape Of Some Of The Key Players
4.1.2 Partnerships, Joint Ventures And Collaborations
4.1.2.1 Key Insights
4.1.2.2 Recent Partnerships, Joint Ventures And Collaborations
4.1.3 Product Launch And Developments
4.1.3.1 Key Insights
4.1.3.2 Recent Product Launch And Developments
4.1.4 Patents, Licensing, Certification And Approvals
4.1.4.1 Key Insights
4.1.4.2 Recent Patents, Licensing, Certification And Approvals
4.1.5 Mergers And Acquisitions
4.1.5.1 Key Insights
4.1.5.2 Recent Mergers And Acquisitions
4.1.6 Business Contracts And Business Expansions
4.1.6.1 Key Insights
4.1.6.2 Recent Business Contracts And Business Expansions
4.1.7 Other Strategies
4.1.7.1 Key Insights
4.1.7.2 Recent Developments Of Other Strategies
4.2 Porter’s Five Forces Analysis
4.2.1 Threat Of Substitutes
4.2.2 Threat Of New Entrants
4.2.3 Bargaining Power Of Buyers
4.2.4 Bargaining Power Of Suppliers
4.2.5 Intensity Of Competitive Rivalry
5 Industry Analysis
5.1 Patent Analysis
5.1.1 Some Of The Key Players
5.1.2 Others (University/Hospital/Person)
5.2 Regulations, Consortiums, Certifications, & Standards
5.2.1 Regulatory Bodies
5.2.2 Examples Of Some Common Acts Certifications
5.3 Value Chain Analysis
6 Global Pharmacogenomics Market By Technology
6.1 Market Segmentation By Technology
6.2 Microarray
6.2.1 Introduction
6.2.2 Microarray: Types, Applications & Key Players
6.2.3 Microarray: Market Dynamics & Recent Developments
6.3 Sequencing
6.3.1 Introduction
6.3.2 Sequencing: Market Dynamics, Applications & Key Players
6.3.3 Types Of Sequencing Technologies
6.3.3.1 Sanger Sequencing
6.3.3.2 Pyrosequencing
6.3.3.3 Next-Gen Sequencing (NGS)
6.3.3.3.1 Next-Gen Sequencing (NGS) Applications & Key Players
6.3.3.3.2 Next-Gen Sequencing (NGS) Recent Developments
6.4 Polymerase Chain Reaction (PCR)
6.4.1 Introduction
6.4.2 PCR Types
6.4.3 PCR: Market Dynamics, Applications & Key Players
6.5 Other Technologies
6.5.1 Mass Spectrometry
6.5.2 Electrophoresis
7 Global Pharmacogenomics Market By Ecosystem Players
7.1 PGX Ecosystem Players: Overview
7.2 Market Segmentation By Ecosystem Players
7.2.1 Market Insights & Statistics
7.3 Diagnostic Test Companies
7.3.1 Introduction
7.3.2 Market Statistics
7.3.3 Diagnostic Companies: Drivers & Challenges
7.3.4 Recent Key Developments
7.3.5 Key Players
7.4 Pharmaceuticals Companies
7.4.1 Introduction
7.4.2 Market Statistics
7.4.3 Drug Development Process
7.4.4 Role Of Pharmaceutical Companies & Example Of Some Drugs
7.4.5 Pharmaceuticals Companies: Drivers & Challenges
7.4.6 Recent Key Developments
7.4.7 Key Players
7.5 Service Providers
7.5.1 Introduction
7.5.2 Market Statistics
7.5.3 Service Provider: Roles & Big Data Benefits
7.5.4 Big Data Companies: Drivers & Challenges
7.5.5 Recent Key Developments
7.5.6 Key Players
8 Global Pharmacogenomics Market By Therapeutic Applications
8.1 Market Segmentation
8.2 Market Statistics
8.3 Cancer/Oncology
8.3.1 Key Insights & Statistics
8.3.2 Market Statistics
8.3.3 Types Of Cancer
8.3.4 Cancer: Examples Of Some Drugs
8.3.5 Cancer: Examples Of Some Tests
8.3.6 Market Dynamics & Key Players
8.3.7 Recent Key Developments
8.4 Cardiovascular Diseases (CVD)
8.4.1 Key Insights & Statistics
8.4.2 Market Statistics
8.4.3 CVD: Examples Of Some Drugs
8.4.4 CVD: Examples Of Some Tests
8.4.5 Recent Key Developments & Key Players
8.5 Central Nervous System(CNS)
8.5.1 Key Insights & Statistics
8.5.2 Market Statistics
8.5.3 CNS: Examples Of Some Drugs
8.5.4 CNS: Examples Of Some Tests
8.5.5 Recent Key Developments & Key Players
8.6 Infectious Diseases
8.6.1 Key Insights & Statistics
8.6.2 Market Statistics
8.6.3 Infectious Diseases : Examples Of Some Drugs
8.6.4 Recent Key Developments & Key Players
8.7 Other Diseases
8.7.1 Key Insights & Statistics
8.7.2 Market Statistics
8.7.3 Other Diseases : Examples Of Some Drugs
8.7.4 Other Diseases : Examples Of Some Tests
8.7.5 Recent Key Developments & Key Players
9 Global Pharmacogenomics Market By Geography
9.1 Geographical Scenario
9.2 Market Insights & Statistics
9.3 North America
9.3.1 Market Scope
9.3.2 North America: Market Insights & Statistics
9.3.3 North American Market Dynamics
9.3.4 Key Regulatory Bodies & Associations
9.3.5 The U.S.
9.3.5.1 The U.S.: Market Statistics
9.3.5.2 The U.S.: Key Insights
9.3.6 Canada
9.3.7 Recent Key Developments
9.4 Europe
9.4.1 Market Scope
9.4.2 Europe: Market Insights & Statistics
9.4.3 European Market Dynamics
9.4.4 Key Regulatory Bodies & Associations
9.4.5 The U.K.
9.4.6 Germany
9.4.7 Recent Key Developments
9.5 Asia-Pacific (APAC)
9.5.1 Market Scope
9.5.2 APAC: Market Insights & Statistics
9.5.3 APAC Market Dynamics
9.5.4 China
9.5.5 Japan
9.5.6 India
9.5.7 Recent Key Developments
9.6 Rest Of The World (ROW)
9.6.1 ROW: Market Insights & Statistics
9.6.2 Middle East
9.6.3 South America
9.6.4 Africa
9.6.5 Recent Key Development
10 Company Overview
10.1 Abbott Laboratories
10.1.1 Overview
10.1.2 Financials
10.1.3 Financial Summary
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Affymetrix, Inc.
10.2.1 Overview
10.2.2 Financials
10.2.3 Financial Summary
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Assurex Health, Inc.
10.3.1 Overview
10.3.2 Key Developments
10.3.3 SWOT Analysis
10.4 Astrazeneca
10.4.1 Overview
10.4.2 Financials
10.4.3 Financial Summary
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 Illumina, Inc.
10.5.1 Overview
10.5.2 Financials
10.5.3 Financial Summary
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Laboratory Corporation Of America Holdings
10.6.1 Overview
10.6.2 Financials & Financial Summary
10.6.3 Key Developments
10.6.4 SWOT Analysis
10.7 Myriad Genetics, Inc.
10.7.1 Overview
10.7.2 Financials & Financial Summary
10.7.3 Key Developments
10.7.4 SWOT Analysis
10.8 Pfizer, Inc.
10.8.1 Overview
10.8.2 Financials
10.8.3 Financial Summary
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Qiagen, Inc.
10.9.1 Overview
10.9.2 Financials
10.9.3 Financial Summary
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Roche Holding AG-BR
10.10.1 Overview
10.10.2 Financials
10.10.3 Financial Summary
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.11 TEVA Pharmaceutical Industries Ltd.
10.11.1 Overview
10.11.2 Financials
10.11.3 Financial Summary
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.12 Thermo Fisher Scientific
10.12.1 Overview
10.12.2 Financials
10.12.3 Financial Summary
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.13 Transgenomic, Inc.
10.13.1 Overview
10.13.2 Financials & Financial Summary
10.13.3 Key Developments
10.13.4 SWOT Analysis
10.14 Other Emerging Companies
10.14.1 Diagnostic Test Companies
10.14.1.1 Companiondx Reference Lab, LLC
10.14.1.2 Mapmy Genome
10.14.1.3 Asuragen
10.14.1.4 23andme
10.14.1.5 Cnsdose
10.14.2 Pharmaceutical Companies
10.14.2.1 Actinium Pharmaceuticals, Inc
10.14.2.2 Foundation Medicine
10.14.3 Service Providers
10.14.3.1 PGX Software LLC
10.14.3.2 Gene Logic
10.14.3.3 Genewiz
10.14.3.4 Conatus Consulting, LLC
10.14.4 Care Providers
10.14.4.1 Gene DX
10.14.4.2 Mayo Clinic
11 List Of Acronyms
List Of Figures
1 Year Consideration
2 Market Classification & Segmentation
3 Research Methodology
4 Global Pharmacogenomics Market ($Billion)
5 Global Pharmacogenomics Market Value, 2015-2022 ($Billion)
6 Global PGX Market, By Ecosystem, 2015-2022 ($Billion)
7 Global PGX Market Share, By Therapeutic Application, 2015-2022 ($Billion)
8 Global Pharmacogenomics Market, By Geography-2022
9 Mechanism Of Action
10 Role Of Companion Diagnostics In PGX
11 Role Of Biomakers In PGX
12 Role Of Molecular Diagnostics IN PGX
13 Benefits Of PGX
14 End-Use Applications Of PGX
15 Market Dynamics
16 Partnerships, Joint Ventures And Collaborations: Key Players Analysis
17 Product Launch And Developments: Key Players Analysis
18 Patents, Licensing, Certification And Approvals : Key Players Analysis
19 Mergers And Acquisitions: Key Players Analysis
20 Business Contracts And Business Expansions : Key Players Analysis
21 Others Strategies: Key Players Analysis
22 Porter’s Five Forces Analysis
23 Threat Of Substitutes
24 Threat Of New Entrants
25 Bargaining Power Of Buyers
26 Bargaining Power Of Suppliers
27 Intensity Of Competitive Rivalry
28 Roles And Responsibilities Of Healthcare Policy Makers
29 Role Of FDA In PGX
30 Classification Of Medical Devices
31 Examples Of Some Common Acts
32 Example Of Some Certifications
33 Value Chain Analysis
34 Example Of Some Significant Players In PGX Value Chain
35 Generalized Process For The Microarray
36 Different Types Of Microarrays
37 Applications Of Microarrays
38 Microarray- Drivers & Challenges
39 Sequencing Technologies In PGX
40 Sequencing - Drivers & Challenges
41 Applications Of Sequencing
42 NGS- Drivers & Challenges
43 Applications Of NGS
44 Generalized Process For PCR
45 Different Types Of PCR
46 PCR - Drivers & Challenges
47 Applications Of PCR
48 Applications Of Mass Spectrometry
49 Applications Of Electrophoresis
50 Overview Of PGX Ecosystem Players
51 Global PGX Market By Ecosystem Players
52 Global Pharmacogenomics Market, By Ecosystem , 2015-2022 ($Billion)
53 Global PGX Ecosystem Market, By Diagnostic Tests Companies, 2015-2022 ($Billion)
54 Global PGX Diagnostic Tests Market, By Therapeutic Applications, 2015-2022 ($Billion)
55 Global PGX Diagnostic Tests Market, By Geography, 2015-2022 ($Billion)
56 Diagnostic Companies- Drivers & Challenges
57 Global PGX Ecosystem Market, By Pharmaceutical Companies, 2015-2022 ($Billion)
58 Global PGX Pharmaceutical Market, By Therapeutic Applications, 2015-2022 ($Billion)
59 Global PGX Pharmaceutical Market, By Geography, 2015-2022 ($Billion)
60 Drug Development Process
61 Role Of Pharmaceuticals Companies
62 Pharmaceuticals Companies- Drivers & Challenges
63 Global PGX Ecosystem Market, By Service Providers, 2015-2022 ($Billion)
64 Global PGX Service Providers Market, By Therapeutic Applications, 2015-2022 ($Billion)
65 Global PGX Service Providers Market, By Geography, 2015-2022 ($Billion)
66 Three Data Drivers Of PGX Market
67 Benefits Of Big Data
68 Big Data Companies- Drivers & Challenges
69 Global PGX Market By Therapeutics Applications
70 Global PGX Market, By Theraeutics Application, 2015-2022 ($Billion)
71 Global PGX Market By Oncology,2015-2022($Billion)
72 Global PGX Oncology Market, By Ecosystem, 2015-2022 ($Billion)
73 Global PGX Oncology Market, By Geography, 2015-2022 ($Billion)
74 Types Of Cancer
75 Oncology Market Dynamics
76 Global PGX Market By CVD, 2015-2022 ($Billion)
77 Global PGX CVD Market, By Ecosystem, 2015-2022 ($Billion)
78 Global PGX CVD Market, By Geography, 2015-2022 ($Billion)
79 Global PGX Market By CNS, 2015-2022 ($Billion)
80 Global PGX CNS Market, By Ecosystem, 2015-2022 ($Billion)
81 Global PGX CNS Market, By Geography, 2015-2022 ($Billion)
82 Global PGX Market By Infectious Diseases, 2015-2022 ($Billion)
83 Global PGX Infectious Diseases Market, By Ecosystem, 2015-2022 ($Billion)
84 Global PGX Infectious Diseases Market, By Geography, 2015-2022 ($Billion)
85 Global PGX Market By Other Diseases, 2015-2022 ($Billion)
86 Global PGX Other Diseases Market, By Ecosystem, 2015-2022 ($Billion)
87 Global PGX Other Diseases Market, By Geography, 2015-2022 ($Billion)
88 Growth Trajectory Of PGX Market
89 Global Pharmacogenomics Market, By Geography , 2015-2022 ($Billion)
90 Global Pharmacogenomics Market, By Geography (2015)
91 North American PGX Market, 2015
92 North American PGX Market, 2015-2022 ($Billion)
93 North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
94 North American Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
95 North American Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
96 North American Market Dynamics
97 Key Regulatory Bodies & Associations
98 The U.S. PGX Market, 2015-2022 ($Billion)
99 The U.S. Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
100 The U.S. Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
101 Canada PGX Market Dynamics
102 European PGX Market, 2015
103 European PGX Market,2015-2022($Billion)
104 European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
105 European Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
106 European Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
107 European Market Dynamics
108 Key Regulatory Bodies & Associations
109 The U.K. PGX Market, 2015-2022 ($Billion)
110 The Germany PGX Market, 2015-2022 ($Billion)
111 APAC Country-Wise CAGR Of PGX Market
112 APAC PGX Market, 2015-2022 ($Billion)
113 APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
114 APAC Pharmacogenomics MARKET,BY Ecosystem, 2015-2022 ($Billion)
115 APAC Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
116 APAC Market Dynamics
117 The China PGX Market, 2015-2022 ($Billion)
118 China Market Dynamics
119 The Japan PGX Market, 2015-2022 ($Billion)
120 The Indian PGX Market, 2015-2022 ($Billion)
121 Indian Market Dynamics
122 Region-Wise CAGR Of PGX Market
123 ROW PGX Market, 2015-2022 ($Billion)
124 ROW PGX Market, By Sub-Region, 2015-2022 ($Billion)
125 ROW PGX Market, By Ecosystem, 2015-2022 ($Billion)
126 ROW PGX Market, By Therapeutics, 2015-2022 ($Billion)
127 Middle East PGX Market, 2015-2022 ($Billion)
128 South American PGX Market, 2015-2022 ($Billion)
129 African PGX Market, 2015-2022 ($Billion)
130 : Abbott Laboratories, Inc.– Overall Financials, 2013-2015 ($Billion)
131 Abbott Laboratories, Inc.- Financials By Business Segments, 2013-2015 ($Billion)
132 Abbott Laboratories, Inc.– Financials By Geography, 2013-2015 ($Billion)
133 Abbott Laboratories, Inc.- SWOT Analysis
134 Affymetrix, Inc.– Overall Financials, 2013-2015 ($Million)
135 Affymetrix, Inc.- Financials By Business Segments, 2013-2015 ($Million)
136 Affymetrix, Inc.– Financials By Geography,2013-2015 ($Million)
137 Affymetrix, Inc.- SWOT Analysis
138 Assurex Health, Inc.- SWOT Analysis
139 Astrazeneca – Overall Financials, 2013-2015 ($Billion)
140 Astrazeneca- Financials By Business Segments, 2013-2015 ($Billion)
141 Astrazeneca– Financials By Geography,2013-2015 ($Billion)
142 Astrazeneca- SWOT Analysis
143 Illumina, Inc.– Overall Financials, 2013-2015 ($Million)
144 Illumina, Inc.- Financials By Business Segments, 2013-2015 ($Million)
145 Illumina, Inc.– Financials By Geography, 2013-2015 ($Million)
146 Illumina, Inc.- SWOT Analysis
147 Laboratory Corporation Of America Holding.- Overall Financials, 2013-2015 ($Million)
148 Laboratory Corporation Of America Holding—Financials By Business Segments, 2013-2015 ($ Million)
149 Laboratory Corporation Of America Holding.- SWOT analysis
150 Myriad Genetics, Inc.– Overall Financials, 2013-2015 ($Million)
151 Myriad Genetics, Inc.– Financials By Business Segments, 2013-2015 ($Million)
152 Myriad Genetics,INC.- SWOT Analysis
153 Pfizer, Inc.– Overall Financials, 2013-2015 ($Billion)
154 Pfizer,Inc. – Financials By Geography ,2013-2015 ($Billion)
155 Pfizer, Inc.- Financials By Business Segments, 2014-2015 ($Billion)
156 Pfizer, Inc.– Financials By Business Segment, 2013
157 Pfizer, Inc.- SWOT analysis
158 Qiagen– Overall Financials, 2013-2015 ($Million)
159 Qiagen- Financials By Business Segments, 2013-2015 ($Million)
160 Qiagen– Financials By Geography, 2013-2015 ($Million)
161 Qiagen- SWOT Analysis
162 Roche Holding– Overall Financials,2013-2015 ($Billion)
163 Roche Holding- Financials By Business Segments, 2013-2015 ($Billion)
164 Roche Holding– Financials Of Diagnostics Division By Geography, 2013-2015 ($Billion)
165 Roche Holding– Financials Of Pharmaceuticals,SEGMENT By Geography, 2013-2015 ($Billion)
166 Roche Holding- SWOT Analysis
167 TEVA Pharmaceutical Ltd.– Overall Financials, 2013-2015 ($Billion)
168 TEVA Pharmaceutical Ltd.- Financials By Business Segments, 2013-2015 ($Billion)
169 TEVA Pharmaceutical Ltd.– Financials By Geography, 2013-2015 ($Billion)
170 TEVA Pharmaceutical Industries Ltd.- SWOT analysis
171 Thermo Fisher, Inc.- Overall Financials, 2013-2015 ($Billion)
172 Thermo Fisher, Inc.— Financials By Business Segments, 2013-2015 ($Billion)
173 Thermo Fisher, Inc.— Financials By Geography, 2013-2015 ($Billion)
174 Thermo Fisher Scientific, Inc.- SWOT Analysis
175 Transgenomic, Inc.- Overall Financials,2013-2015 ($Million)
176 Transgenomic, Inc.- Financials By Business SEGEMENTS, 2013-2015 ($Million)
177 Transgenomic, Inc.- SWOT Analysis
List of Tables
1 Competitive Landscape: Some Of The Key Players
2 Recent Partnerships, Joint Ventures And Collaborations
3 Recent Product Launch And Developments
4 Recent Patents, Licensing, Certification And Approvals
5 Recent Mergers And Acquisitions
6 Recent Business Contracts And Business Expansions
7 Recent Developments Of Other Strategies
8 Patent Analysis Of Some Key Players
9 Patent Analysis Of Some University/Hospital/Person
10 Microarray- Recent Key Developments
11 NGS- Recent Key Developments
12 Difference Between Realt Time & Digital PCR
13 Diagnostic Test Companies- Recent Key Developments
14 Example Of Some Pharmacogenomic Drugs
15 Pharmaceuticals Companies- Recent Key Developments
16 Service Providers- Recent Key Developments
17 Cancer- Examples Of Some Drugs
18 Cancer- Examples Of Some Tests
19 Oncology- Recent Key Developments
20 CVD- Examples Of Some Drugs
21 CVD- Examples Of Some Tests
22 CNS- Examples Of Some Drugs
23 CNS- Examples Of Some Tests
24 Infectious Diseases- Examples Of Some Drugs
25 Other Diseases- Examples Of Some Drugs
26 North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
27 North American Pharmacogenomics Market Recent Key Dvelopments
28 European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
29 European PGX Market Recent Key Developments
30 APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
31 APAC Pharmacogenomics Market Recent Key Developments
32 ROW Pharmacogenomics Market,By Sub-Region, 2015-2022
33 ROW Recent Key Development
34 Abbott Laboratories, Inc. Recent Developments
35 Affymetrix, Inc. Recent Developments
36 Assurex Health, Inc. Recent Developments
37 Astrazeneca Recent Developments
38 Illumina, Inc. Recent Developments
39 Laboratory Corporation Of America Holding Recent Developments
40 Myriad Genetics Recent Developments
41 Pfizer, Inc. Recent Developments
42 Qiagen Recent Developments
43 Roche Holding Recent Developments
44 TEVA Pharmaceutical Industries Ltd. Recent Developments
45 Thermo Fisher, Inc. Recent Developments
46 Transgenomic, Inc. Recent Developments

The global Pharmacogenomics (PGx) market growth is gradually gaining speed as large number of government initiatives and research & development programs have been launched in the last few years.Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022. 

The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorders/abnormalities, and government support and regulations.The report has been further classified on the basis of ecosystem players, therapeutic applications, and geographical regions. Ecosystem is further segmented into: Pharmaceuticals companies, Diagnostic Companies, and Service Providers which includes Software & Healthcare database providers, Hospitals & Care Providers and Insurance Providers. 

Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatment, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others.

In North America, existing players are integrating with new start-ups through partnerships and collaboration to capture the North American segment. North American local players are entering in other developing regions to capture more market share. Throughout the Asia-Pacific and European countries, regulatory bodies are rolling out regulations to keep a check on latest technologies. 

North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of 12.14% CAGR from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at 18.74% CAGR from 2016 to 2022.

The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to develop specific laboratory diagnostic tests.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS